Follow-on biologics : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007., by United States Senate Committee on Health, Education, Labor, and Pensions

Title:	Follow-on biologics : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007.
Author:	United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions
Note:	U.S. G.P.O. :, 2008

Link:	page images at HathiTrust
No stable link:	This is an uncurated book entry from our extended bookshelves, readable online now but without a stable link here. You should not bookmark this page, but you can request that we add this book to our curated collection, which has stable links.

Subject:	Drug development -- Government policy -- United States
Subject:	Pharmaceutical biotechnology -- Government policy -- United States
Subject:	Pharmaceutical biotechnology -- United States -- Patents
Subject:	Pharmaceutical technology -- Government policy -- United States
Other copies:	Look for editions of this book at your library, or elsewhere.